<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar2240</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>Characterization of immunoglobulin mutations in humans with activation-induced cytidine deaminase deficiency</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Longo</snm>
               <mi>S</mi>
               <fnm>Nancy</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Satorius</snm>
               <fnm>Colleen</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Durandy</snm>
               <fnm>Anne</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A4">
               <snm>Lipsky</snm>
               <mi>E</mi>
               <fnm>Peter</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, USA</p>
            </ins>
            <ins id="I2">
               <p>Hopital Necker-Enfants Malades, Paris, France</p>
            </ins>
         </insg>
         <source>Arthritis Research &amp; Therapy</source>
         <supplement>
            <title>
               <p>6<sup>th </sup>Global Arthritis Research Network (GARN) Meeting</p>
            </title>
            <editor>Steffen Gay and Peter E Lipsky</editor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>6<sup>th </sup>Global Arthritis Research Network (GARN) Meeting</p>
            </title>
            <location>Zurich, Switzerland</location>
            <date-range>10&#8211;13 May 2007</date-range>
            <url>http://www.ciaomed.org/garn.cfm</url>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2007</pubdate>
         <volume>9</volume>
         <issue>Suppl 3</issue>
         <fpage>P14</fpage>
         <url>http://arthritis-research.com/content/9/S3/P14</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar2240</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>19</day>
               <month>10</month>
               <year>2007</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2007</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>Somatic hypermutation (SHM) is initiated in germinal center (GC) B cells expressing high levels of activation-induced cytidine deaminase (AID), which targets WRC (W = A/T, R = A/G) motifs generating a uracil:guanidine mismatch. During SHM, 73% of the mutations are attributed to AID and error-prone polymerase eta (POL&#951;). To characterize the nature of other mutations, 316 genomic nonproductive V(D)J rearrangements amplified and sequenced from three AID<sup>-/- </sup>patients were analyzed. The mutation frequency was 20-fold less than normals (0.09% versus 2%) but ~5 &#215; 10<sup>4</sup>-fold more than non-B cells. Reduced RGY (6% versus 27%) and WRC (6% versus 15%) motif mutations and decreased replacements in complementarity determining regions were attributed to the lack of AID. Reduced WA motif mutations (12% versus 23%) suggested POL&#951; activity was decreased. Prominent G>C and A>T biases suggested that mutation and repair mechanisms occurred preferentially on one DNA strand. A high percentage of the mutations were G substitutions on the sense strand (43% versus 29% in normals), reflecting C mutational targeting on the opposite strand. These were primarily G to A transitions, suggesting that UNG activity was reduced even though UNG is upregulated in normal GC B cells and large GCs occur in AID<sup>-/- </sup>patients. The mutation pattern suggests that AID-independent C substitutions contribute a small proportion of SHM but lack the targeting provided by AID. Finally, a low level of SHM clearly can develop in the absence of AID; however, this mechanism is inefficient at altering the binding capacity of immunoglobulin heavy chain genes.</p>
      </sec>
   </bdy>
</art>
